Cargando…
A Rare Case of Pembrolizumab-Associated Graves’ Disease
Immune checkpoint inhibitors (ICPis), such as pembrolizumab (Keytruda®), are associated with the development of several immune-related adverse events (irAEs). Thyroid dysfunction is a common endocrine irAE associated with pembrolizumab; however, Graves’ disease induced by pembrolizumab is extremely...
Autores principales: | Alqaisi, Sura, Rahman, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998112/ https://www.ncbi.nlm.nih.gov/pubmed/36909047 http://dx.doi.org/10.7759/cureus.34696 |
Ejemplares similares
-
LBODP100 A Rare Case Of Pembrolizumab Induced Graves’ Disease
por: Alqaisi, Sura, et al.
Publicado: (2022) -
Routine Screening Mammogram Leading to the Incidental Diagnosis of a Metastatic Neuroendocrine Breast Cancer (NEBC) from an Unrecognized Asymptomatic Small Bowel Neuroendocrine Tumor
por: Alqaisi, Sura, et al.
Publicado: (2022) -
ODP175 COVID-19 Induced Euglycemic Diabetic Ketoacidosis in a Patient taking Sodium-Glucose Cotransporter-2 Inhibitors
por: Alqaisi, Sura, et al.
Publicado: (2022) -
ODP649 COVID-19 Induced Diabetic Ketoacidosis Which Unmasked Latent Autoimmune Diabetes In Adult
por: Alqaisi, Sura, et al.
Publicado: (2022) -
Granulomatosis With Polyangiitis in Untreated Graves’ Disease: A Rare Event
por: Moosa, Syed Ahmad, et al.
Publicado: (2022)